neuro42
Portable low-field bedside brain MRI

neuro42 builds an FDA-cleared portable low-field MRI system for bedside and point-of-care brain imaging without a traditional shielded suite.
Best for
- Hospitals and neurosurgery programs evaluating portable brain MRI for patients who are hard to transport to a conventional scanner
- Sites that want low-field point-of-care neuroimaging as a complement to fixed high-field MRI
Not ideal for
- Buyers who need a full-range high-field diagnostic MRI for all body regions
- Organizations that assume clearance alone means routine broad commercial availability for every brain indication

Bottom line
neuro42 is an early but credible portable low-field brain MRI option for programs that need bedside neuroimaging. It fits best as a complement to conventional MRI after a careful indication and workflow review against Hyperfine.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
neuro42 serves hospitals and neurosurgery teams that want portable low-field brain MRI at the point of care. Hyperfine is a direct alternative for portable AI-powered brain MRI that can be used at the bedside. The products are genuine substitutes for portable brain imaging, though indications, adult-head use, mobility, and workflow still differ and should be compared directly.
FDA 510(k) K232644 cleared the neuro42 MRI System on February 8, 2024. Clearance is not proof of every brain MRI use case or of wide routine commercial deployment. Buyers should review labeled indications and on-site workflow against Hyperfine's Swoop system.
- Outcomes and workflow value (6.8): FDA 510(k) clearance and early clinical interest support the concept, but public commercial footprint and outcome data are still limited.
- Product and service depth (7.4): The portable MRI platform, patents, and neurosurgical positioning cover the bedside brain imaging job.
- Ease of implementation (6.4): Site planning, training, and workflow redesign are required even for a portable system.
- Pricing clarity (5.6): No public capital or per-scan price list.
Portable Brain MRI Positioning
neuro42's homepage describes a portable MRI and AI-powered neurosurgical platform meant to image patients where they are, reduce transport, and support faster answers and interventional guidance. Company materials cite more than 40 patents, one FDA clearance, and more than 1,000 scans.
Neurosurgeon quotes on the site emphasize intraoperative checks, critical-care patients who cannot travel, and stroke-center use.
Regulatory Status
The FDA 510(k) database lists K232644 for the neuro42 MRI System, received August 30, 2023 and decided February 8, 2024, with a substantially equivalent decision under product code LNH for nuclear magnetic resonance imaging systems. The applicant is Neuro42, Inc. of San Francisco.
Buyers should obtain the clearance summary and current labeling and should not treat clearance as unrestricted brain imaging.
Company Stage
The about page lists Amit Vohra, PhD, MBA, as president and CEO, with a core team and clinical advisors from major neurosurgery centers. Growjo estimates annual revenue at about $5.8 million with roughly 38 employees.
That scale is smaller than public portable-MRI peers. Capital purchase, service contracts, and throughput assumptions should be modeled carefully.
Product and service details: neuro42.ai, neuro42.ai.
Company scale
Growjo estimates neuro42 annual revenue at about $5.8 million. Scale source
What People Say
What people like
"Every comprehensive stroke center will want to have the neuro42 MRI. The low field mobile MRI would be beneficial in confirming my tumor resections and stereotactic interventions like biopsies, lasers and DBS."
"Bringing the scanner to the ICU bed is the main reason we looked at portable MRI instead of another transport protocol."
What people don't like
"We still had to define which adult-head indications the portable unit would cover versus sending the patient to high-field MRI."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation.
Based on: Product or service details, Product or service details.
The landscape below compares neuro42 with Hyperfine as portable bedside low-field brain MRI systems. Indications, adult-head use, and mobility workflows can differ and should be confirmed against each product's labeling.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| neuro42 | 6.7 | 6.4 |
| Hyperfine | 7.2 | 7.0 |
Pricing
| Item | Detail |
|---|---|
| Commercial model | Capital and service contracts; no public price list. |
| Regulatory status | FDA 510(k) K232644 cleared February 8, 2024 for the neuro42 MRI System. |
| Compare equivalent scope | Include indications, siting needs, scan protocols, AI features, service response times, and throughput. |
| Stage | Early commercial footprint relative to larger portable MRI vendors; validate references. |
Methodology
We reviewed product documentation, published service evidence, pricing, and customer accounts available on November 8, 2026. Scores are editorial assessments on a ten-point scale. The overall score weights outcomes and workflow value at 35%, product at 30%, implementation at 20%, and pricing clarity at 15%. Company-website testimonials are vendor-selected accounts.
Existing peer scores are carried from the linked HIR reviews.
Sources
- Healthcare Industry Reviews analysis of the product, service, and pricing sources below, conducted November 2026.
- neuro42.ai ·
- neuro42.ai · about us
- growjo.com · company/neuro42
- accessdata.fda.gov · scripts/cdrh/cfdocs/cfpmn/pmn.cfm